ABSTRACT-TTC-909is a newly developed isocarbacyclin methyl ester (TEI-9090) incorporated in lipid microspheres. The neuroprotective effect of TTC-909 was histologically examined in the pyramidal cell layer of the hippocampus CA1 subfield 7 days after transient forebrain ischemia using stroke-prone sponta neously hypertensive rats. TTC-909, given intravenously 10 min after the transient forebrain ischemia, dose-dependently protected against ischemia-related delayed neuronal death. The blood pressure remained unchanged following TTC-909 administration. This finding suggests that TTC-909 has a neuroprotective action on ischemic delayed neuronal death in the hippocampus.
Keywords:Ischemia-related delayed neuronal death, Prostacyclin analogue, Stroke-prone spontaneously hypertensive rat Prostacyclin (PGI2) has potent vasodilating and anti platelet activities (1). However, the clinical use of PGI2 is limited because of its unstable and short-lasting prop erties (1). Isocarbacyclin is one of the stable analogues of PGI2, and TEI-9090, isocarbacyclin methyl ester (methyl 5 { (1 S, 5S, 6R, 7R)-7-hydroxy-6 [(E)-(S)-3-hydroxy l -oc tenyl]bicyclo[3.3.01oct-2-en-3-yl}pentanoate, CAS 88931 51-5), is also a chemically stable isocarbacyclin methyl ester (2). TTC-909 is a drug preparation of TEI-9090 in corporated into lipid microspheres. TTC-909 has been shown to possess both vasodilative and anti-platelet activity, similar to PGI2 (3). In an experiment with a hamster cheek-pouch model, the anti-thrombotic activ ity of TTC-909 was more potent than that of PGI2 (4). One advantage of TTC-909 over natural PGI2 is its accumulation of coating lipid microspheres around the damaged blood vessel walls (5). TTC-909 is thus expected to be of clinical usefulness in the treatment of peripheral vascular disorders. On the other hand, TTC-909 im proved the post-ischemic decrease and increase of cerebral blood flow and blood-brain barrier permeabil ity, respectively, and prevented ischemic brain edema produced by occluding the middle cerebral artery in stroke-prone spontaneously hypertensive rats (SHRSP) (6). Thus TTC-909 seems to prevent delayed neuronal death evoked by transient forebrain ischemia. Ozagrel, a highly selective inhibitor of thromboxane A2 synthase, is used as a therapeutic agent for thromboembolic disor ders, cerebral circulatory disorders, ischemic heart diseases and asthma (7). Ozagrel inhibits both the spasms of the basilar artery and the decreases in regional cerebral blood flow, by reducing thromboxane A2 production and in creasing PGI2 production (7). We report here the effect of TTC-909 and ozagrel on the delayed neuronal death in duced by transient forebrain ischemia in SHRSP with the two-vessel occlusion model. SHRSP with two-vessel oc clusion is a useful model for examining delayed neuronal death in the hippocampus caused by a transient forebrain ischemia (8, 9). This model is suitable for examining the post-ischemic conditions in human, because the microvascular disorder such as lacunar infarction is con sidered to ...